Lung Transplant Rejection Clinical Trial
Official title:
A Longitudinal Study of Donor-Derived Cell Free DNA in Lung Transplant
Lung transplant is a viable treatment strategy for many with end-stage lung diseases. Despite advances in both the surgical and medical management, lung transplant recipients experience episodes of allograft insult and injury that lead to dysfunction and ultimately contribute to graft failure. The primary noninvasive tool for monitoring the lung allograft, pulmonary function testing, is neither sensitive nor specific for lung allograft injury which makes the management of lung transplant recipients particularly challenging. A decline in pulmonary function tests prompts invasive procedures such as bronchoscopy with transbronchial lung biopsy to diagnose the cause of allograft injury, although this, too, is not 100% sensitive, and oftentimes patients are treated empirically for rejection when no other etiology for lung function decline is identified. Empiric treatment prompted by extrapulmonary drivers of decline in lung function may result in inappropriate exposure to risks of augmented immunosuppression. The purpose of this study is to determine to what extent monitoring of donor-derived cell free DNA in lung transplant recipients can be used as a marker of lung injury and stability.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT06309628 -
Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy
|
||
| Withdrawn |
NCT02893176 -
Macitentan in the Treatment of Organ Rejection After Lung Transplantation
|
Phase 4 | |
| Completed |
NCT02441413 -
Transplant Optimization Using Functional Imaging (TROFI)
|
N/A | |
| Recruiting |
NCT05375149 -
Exhaled Breath Particles in Lung Transplantation
|
||
| Active, not recruiting |
NCT03967340 -
PREdiction of Chronic LUng Allograft Dysfunction
|
||
| Active, not recruiting |
NCT05260372 -
Next Generation Sequencing to Detect Acute Rejection in Lung Transplant Patients.
|
||
| Recruiting |
NCT06082037 -
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
|
Phase 3 | |
| Recruiting |
NCT04714801 -
Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05170425 -
LAMBDA 002 (Lung Registry) Study
|
||
| Completed |
NCT02474927 -
Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation
|
Phase 2 | |
| Recruiting |
NCT05006742 -
Comparison of Transbronchial Cryobiopsy and Forceps Biopsy in Lung Transplant Recipients
|
N/A | |
| Recruiting |
NCT02812290 -
Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation
|
||
| Not yet recruiting |
NCT03500575 -
Extracorporeal Photopheresis in Lung Transplant Rejection for Cystic Fibrosis (CF) Patients
|
N/A | |
| Withdrawn |
NCT03805178 -
Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization
|
Phase 2 | |
| Completed |
NCT03359863 -
Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
|
Phase 2 | |
| Active, not recruiting |
NCT03656926 -
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2)
|
Phase 3 | |
| Completed |
NCT01985412 -
Genome Transplant Dynamics: Non-invasive Sequencing-based Diagnosis of Rejection
|
||
| Recruiting |
NCT04837339 -
Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation
|
N/A | |
| Recruiting |
NCT03090581 -
Transbronchial Biopsies With Cryoprobe in Patients With Lung Transplantation.
|
N/A | |
| Recruiting |
NCT06112951 -
A Prospective Randomized Trial of ECP in Subclinical AMR
|
N/A |